DF/HCC Kidney Cancer SPORE Tissue, Acquisition, Pathology and Clinical Data Core 2

摘要： 组织采集、病理学和临床数据（TAPCD）核心的首要目标是维护 并扩大现有的标本库，包括肾脏病患者的组织、血液和尿液。 同意将他们的样本与临床数据联系起来的肿瘤。此组件包括 收集、冷冻和储存肾癌和配对非肿瘤组织的新鲜样品;收集， 血液和尿液的处理和储存;固定组织样本的鉴定和提供， 包括从活检和肾切除术样品中构建组织微阵列（TMA）， 同意分析这些组织的患者。caTissue系统，也就是NCI caBIG用于生物标本库存管理的生物储存库工具，目前用于跟踪标本 通过使用条形码技术，通过请求、运输和接收过程的每一个步骤。 重要的是，TAPCD核心将继续维护所有知情同意的临床数据数据库（CRIS）。 RCC患者。通过使用标准化的病理学审查程序，提高了数据库的价值 和数据收集程序。该数据库和标本跟踪系统提供了一个信息链接 在参与的丹娜-法伯/哈佛癌症中心（DF/HCC）医院中，包括丹娜-法伯 癌症研究所和布里格姆妇女医院（DFCI/BWH），贝斯以色列女执事医疗中心 （BIDMC）和马萨诸塞州总医院（MGH）。这允许无缝共享样本 与临床结果数据相关联的资源，支持安全的数据管理系统， 所有参与机构的SPORE研究者。保护患者隐私 在整个过程中，从标本收集到用于研究项目。生物统计学和 Bioinformatics Core目前并将继续负责协助数据分析、数据审核和 质量控制 最后，TAPCD Core已经并将继续为SPORE调查人员提供各种服务 这对于成功进行人类肾脏肿瘤以及动物模型的分子分析至关重要。这些服务 包括：对实验中使用所有肿瘤样品进行组织病理学检查和质量控制分析 研究;冷冻组织样本的宏观解剖和石蜡包埋或冷冻组织的载玻片显微解剖 组织，以确保实验研究中使用的样本的高肿瘤细胞性;激光捕获 显微切割（LCM）以提供超纯肿瘤样本;常规免疫组织化学的性能 (IHC)和多参数免疫荧光（IF）染色对人肾癌（TMA或整个组织 部分）;优化和验证用于IHC和IF的已知和新型蛋白质的抗体;分析 广泛的IHC和多重IF染色使用计算机辅助图像分析;开发新的 RCC模型。

Summary: The first and foremost goal of the Tissue Acquisition, Pathology, and Clinical Data (TAPCD) Core is to maintain and expand the existing repository for specimens, including tissues, blood and urine from patients with kidney tumors that have given consent to link their samples to clinical data. Included in this component are the collection, freezing, and storage of fresh samples of kidney cancer and paired non-tumor tissue; the collection, processing and storage of blood and urine; the identification and provision of samples of fixed tissues, including construction of tissue microarrays (TMAs) from biopsy and nephrectomy samples obtained from patients who have consented to allow analysis of these tissues. The caTissue system, which is the NCI caBIG's biorepository tool for biospecimen inventory management, is currently used to track specimens through every step of the requesting, shipping, and receiving process through the use of barcode technology. Importantly, the TAPCD Core will continue to maintain a database of clinical data (CRIS) on all consenting RCC patients. The value of the database is enhanced by the use of standardized pathology review procedures and data collection procedures. The database and specimen tracking system provide an informatics link among the participating Dana-Farber/Harvard Cancer Center (DF/HCC) hospitals, including the Dana-Farber Cancer Institute and Brigham and Women’s Hospital (DFCI/BWH), the Beth Israel Deaconess Medical Center (BIDMC), and the Massachusetts General Hospital (MGH). This allows seamless sharing of specimen resources, linked to clinical outcome data, behind a secure data management system that is available to SPORE investigators at all participating institutions. The protection of patient confidentiality is guarded throughout the whole process, from specimen collection to use in research projects. The Biostatistics and Bioinformatics Core is and will continue to be responsible for assisting in the data analysis, data auditing and quality control. Finally, TAPCD Core has provided and will continue to provide SPORE investigators a variety of services critical to successful molecular analysis of human kidney tumors as well as animal models. These services include: histopathologic review and quality control analysis of all tumor samples utilized in experimental studies; macrodissection of frozen tissue samples and slide microdissection of paraffin-embedded or frozen tissues to ensure high neoplastic cellularity for samples utilized in experimental studies; laser capture microdissection (LCM) to provide ultra-pure tumor samples; performance of routine immunohistochemistry (IHC) and multiparametric immunofluorescence (IF) stains on human kidney cancers (TMAs or whole tissue sections); optimization and validation of antibodies to known and novel proteins for use in IHC and IF; analysis of a broad range of IHC and multiplex IF stains using computer-assisted image analysis; development of novel RCC models.